Applying Process Optimization and Process Intensification to Cell and Gene Therapy Manufacturing

• What do we mean by process intensification and process optimization?
• How can process intensification and optimization decrease cost of dose, accelerate time to market, and minimize risks in cell and gene therapy manufacturing?
• What challenges are encountered when optimizing processes and applying process intensification to cell and gene therapies, and how can drug developers overcome them?

Moderated by: Emmanuelle Cameau, Strategic Technology Partnership Leader, Cytiva 

Panel with Q&A:

• Manuel Carrondo, Full Professor of Chemical and Biochemical Engineering, UNL, Vice-President, iBET
• Alessandra De Riva, Head of Process Development and R&D, Advent Bioservices Ltd
• Marc Davies, Vice President of R&D, Leucid Bio  
• Ben Weil, Director of Manufacturing, INmune Bio
• Sofia Venceslau, Senior Project Manager, ReciBioPharm